Complex
regional pain syndrome (CRPS) is a type of chronic pain that affects one limb of the body
(hand, leg, arm, or foot). The condition generally arises due to severe
injuries or malfunctioning of central and peripheral nervous systems.
Request
to Get Free Sample Pages at:
CRPS is
categorized into two main types: CRPS-I and CRPS-II. CRPS-I is associated with
unconfirmed nerve injury; whereas, CRPS-II is associated with confirmed nerve
injury. CRPS can be characterized by ‘pins and needles’, or ‘burning
sensation’; or it feels like someone squeezing the affected limb. People having
CRPS generally experience change in skin color and temperature, and swelling in
the affected area.
Access
Detailed Report Summary:
Axsome
Therapeutics Inc., and Grünenthal Group are two major companies involved in the
development of drugs for the management of CRPS. The Grünenthal Group is in the
process of developing T121, a bone resorption inhibitor, for the treatment of
CRPS. Axsome Therapeutics Inc. is also developing AXS-02 as a bone resorption
factor inhibitor for the treatment of CRPS.
Make
Enquiry Before Buying the Report:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment